SMAD3 regulates gonadal tumorigenesis.

Area of Science:

• Endocrinology
• Molecular Biology
• Oncology

Background:

• Inhibin acts as a tumor suppressor and activin antagonist.
• Inhibin alpha-deficient mice develop gonadal tumors and a cachexia-like syndrome due to elevated activin signaling.
• SMAD2 and SMAD3 are known in vitro activin signal transducers.

Purpose of the Study:

• To investigate the role of SMAD3 in gonadal tumorigenesis and cachexia.
• To generate and analyze inhibin alpha and Smad3 double mutant mice.

Main Methods:

• Generation of double knockout mice lacking both inhibin alpha and Smad3.
• Phenotypic analysis of tumor development, survival rates, and cachexia-related symptoms in mutant mice.
• Comparison between single and double knockout mice.

Main Results:

• Double knockout males showed significant protection against early tumorigenesis and wasting syndrome, with increased survival to 26 weeks.
• Testicular tumors in double knockout males were absent, unilateral, slow-growing, or less hemorrhagic compared to controls.
• Ovarian tumor development and wasting syndrome were delayed but still occurred in double knockout females, showing typical activin-induced pathological changes.

Conclusions:

• SMAD3 plays a crucial role in gonadal tumorigenesis, with a more pronounced effect in males, suggesting it's a primary transducer in male gonadal tumors.
• SMAD3 function in ovarian tumorigenesis may overlap with SMAD2.
• The cachexia syndrome might be mediated by SMAD2 and SMAD3, or solely by SMAD2 in specific organs, highlighting sexually dimorphic functions of SMAD3.